OBJECTIVE: To evaluate novel eligibility criteria and outreach methods to identify and recruit women at high risk of HIV-1 infection in the Caribbean. METHODS: A prospective cohort study was conducted in 2009-2012 among 799 female commercial sex workers in the Dominican Republic, Haiti, and Puerto Rico. Minimum eligibility criteria included exchange of sex for goods, services, or money in the previous 6 months and unprotected vaginal or anal sex with a man during the same period. Sites used local epidemiology to develop more stringent eligibility criteria and recruitment strategies. Participants were asked questions about HIV/AIDS and their level of concern about participating in an HIV vaccine trial. Logistic regression modeling was used to assess predictors of prevalent HIV infection and willingness to participate in a future HIV vaccine study. RESULTS: HIV prevalence at screening was 4.6%. Crack cocaine use [odds ratio (OR) = 4.2, 95% confidence interval (CI) (1.8-9.0)] was associated with and having sex with clients in a hotel or motel [OR = 0.5, CI (0.3-1.0)] was inversely associated with HIV infection. A total of 88.9% of enrolled women were definitely or probably willing to participate in a future HIV vaccine trial. CONCLUSIONS: This study indicated that local eligibility criteria and recruitment methods can be developed to identify and recruit commercial sex workers with higher HIV prevalence than the general population who express willingness to join an HIV vaccine trial.
OBJECTIVE: To evaluate novel eligibility criteria and outreach methods to identify and recruit women at high risk of HIV-1 infection in the Caribbean. METHODS: A prospective cohort study was conducted in 2009-2012 among 799 female commercial sex workers in the Dominican Republic, Haiti, and Puerto Rico. Minimum eligibility criteria included exchange of sex for goods, services, or money in the previous 6 months and unprotected vaginal or anal sex with a man during the same period. Sites used local epidemiology to develop more stringent eligibility criteria and recruitment strategies. Participants were asked questions about HIV/AIDS and their level of concern about participating in an HIV vaccine trial. Logistic regression modeling was used to assess predictors of prevalent HIV infection and willingness to participate in a future HIV vaccine study. RESULTS: HIV prevalence at screening was 4.6%. Crack cocaine use [odds ratio (OR) = 4.2, 95% confidence interval (CI) (1.8-9.0)] was associated with and having sex with clients in a hotel or motel [OR = 0.5, CI (0.3-1.0)] was inversely associated with HIV infection. A total of 88.9% of enrolled women were definitely or probably willing to participate in a future HIV vaccine trial. CONCLUSIONS: This study indicated that local eligibility criteria and recruitment methods can be developed to identify and recruit commercial sex workers with higher HIV prevalence than the general population who express willingness to join an HIV vaccine trial.
Authors: Donald P Francis; William L Heyward; Vladimir Popovic; Patti Orozco-Cronin; Karin Orelind; Carolyn Gee; Adrian Hirsch; Tina Ippolito; Aimee Luck; Michael Longhi; Vineeta Gulati; Nathan Winslow; Marc Gurwith; Faruk Sinangil; Phillip W Berman Journal: AIDS Date: 2003-01-24 Impact factor: 4.177
Authors: Patria Rojas; Robert Malow; Beverly Ruffin; Eugenio M Rothe; Rhonda Rosenberg Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2011-03-02
Authors: Jonathan D Fuchs; Magda E Sobieszczyk; Scott M Hammer; Susan P Buchbinder Journal: J Acquir Immune Defic Syndr Date: 2010-12 Impact factor: 3.731
Authors: G R Seage; S E Holte; D Metzger; B A Koblin; M Gross; C Celum; M Marmor; G Woody; K H Mayer; C Stevens; F N Judson; D McKirnan; A Sheon; S Self; S P Buchbinder Journal: Am J Epidemiol Date: 2001-04-01 Impact factor: 4.897
Authors: T H Brewer; J Hasbun; C A Ryan; S E Hawes; S Martinez; J Sanchez; M Butler de Lister; J Constanzo; J Lopez; K K Holmes Journal: AIDS Date: 1998-10-01 Impact factor: 4.177
Authors: Susan P Buchbinder; Barbara Metch; Sarah E Holte; Susan Scheer; Anne Coletti; Eric Vittinghoff Journal: J Acquir Immune Defic Syndr Date: 2004-05-01 Impact factor: 3.731
Authors: Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson Journal: Lancet Date: 2008-11-13 Impact factor: 79.321
Authors: Gaston Djomand; Barbara Metch; Carmen D Zorrilla; Yeycy Donastorg; Martin Casapia; Tonya Villafana; Jean Pape; Peter Figueroa; Marianne Hansen; Susan Buchbinder; Chris Beyrer Journal: J Acquir Immune Defic Syndr Date: 2008-05-01 Impact factor: 3.731
Authors: Kate Shannon; Steffanie A Strathdee; Shira M Goldenberg; Putu Duff; Peninah Mwangi; Maia Rusakova; Sushena Reza-Paul; Joseph Lau; Kathleen Deering; Michael R Pickles; Marie-Claude Boily Journal: Lancet Date: 2014-07-22 Impact factor: 79.321
Authors: Marie M Deschamps; Barbara Metch; Cecilia A Morgan; Carmen D Zorilla; Yeycy Donastorg; Edith Swann; Dadaille Taina; Joseph Patrice; William J Pape Journal: J Acquir Immune Defic Syndr Date: 2016-01-01 Impact factor: 3.731
Authors: Henna Budhwani; Kristine R Hearld; Julia Hasbún; Sarah G Franklin; Bijal G Vashi; Nicholas A Cataldo; Donaldson F Conserve; John Waters Journal: AIDS Patient Care STDS Date: 2020-11 Impact factor: 5.078
Authors: Branwen Nia Owen; Rebecca F Baggaley; Jocelyn Elmes; Amy Harvey; Zara Shubber; Ailsa R Butler; Romain Silhol; Peter Anton; Barbara Shacklett; Ariane van der Straten; Marie-Claude Boily Journal: AIDS Behav Date: 2020-03
Authors: Joyce L Browne; Connie O Rees; Johannes J M van Delden; Irene Agyepong; Diederick E Grobbee; Ama Edwin; Kerstin Klipstein-Grobusch; Rieke van der Graaf Journal: Trop Med Int Health Date: 2019-01-08 Impact factor: 2.622
Authors: S A Abdulhaqq; C Zorrilla; G Kang; X Yin; V Tamayo; K E Seaton; J Joseph; S Garced; G D Tomaras; K A Linn; A S Foulkes; L Azzoni; M VerMilyea; C Coutifaris; A V Kossenkov; L Showe; E N Kraiselburd; Q Li; L J Montaner Journal: Mucosal Immunol Date: 2015-11-11 Impact factor: 7.313
Authors: Frances H Ampt; Lisa Willenberg; Paul A Agius; Matthew Chersich; Stanley Luchters; Megan S C Lim Journal: BMJ Open Date: 2018-09-17 Impact factor: 2.692
Authors: Theodora Mbunda; Edith A M Tarimo; Muhammad Bakari; Eric Sandström; Asli Kulane Journal: BMC Public Health Date: 2019-11-20 Impact factor: 3.295